- Title: Hyaluronan in COVID-19 morbidity, a bedside-to-bench approach to understand
   mechanisms and long-term consequences of hyaluronan.
- Urban Hellman<sup>1,2</sup>, Ebba Rosendal<sup>1,3</sup>, Joakim Lehrstrand<sup>4</sup>, Johan Henriksson<sup>3,5</sup>, Tove Björsell<sup>6</sup>,
  Max Hahn<sup>4</sup>, Björn Österberg<sup>7</sup>, Luiza Dorofte<sup>8</sup>, Emma Nilsson<sup>1,3</sup>, Mattias N.E. Forsell<sup>1</sup>, Anna
  Smed-Sörensen<sup>7</sup>, Anna Lange<sup>9</sup>, Mats Karlsson<sup>8</sup>, Clas Ahlm<sup>1</sup>, Anders Blomberg<sup>2</sup>, Sara
  Cajander<sup>9</sup>, Ulf Ahlgren<sup>4</sup>, Alicia Edin<sup>10</sup>, Johan Normark<sup>1,11</sup> Anna K Överby<sup>1,3\*</sup> and Annasara
  Lenman<sup>1\*</sup>
- <sup>1</sup>Department of Clinical Microbiology, Umeå University, Umeå, Sweden
- <sup>9</sup> <sup>2</sup>Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
- <sup>3</sup>The laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå,

11 Sweden

- <sup>4</sup>Umeå Centre for Molecular Medicine (UCMM), Umeå University, Umeå, Sweden
- <sup>5</sup>Department of Molecular Biology, Umeå Centre for Microbial Research (UCMR), and Icelab,
- 14 Umeå University, Umeå, Sweden
- <sup>6</sup>Centre for Clinical Research and Education, Region Värmland, Karlstad, Sweden
- <sup>7</sup>Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
- 17 Karolinska University Hospital, Stockholm, Sweden
- <sup>8</sup>Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University,
- 19 Örebro, Sweden
- <sup>9</sup>Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University,
- 21 Örebro, Sweden
- <sup>10</sup> Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
- <sup>11</sup>Wallenberg Centre for Molecular Medicine, Umeå University, Sweden
- 24 *\*These authors contributed equally*
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

Correspondence and requests for reprints should be addressed to Ph.D. Annasara Lenman,
Department of Clinical Microbiology, Umeå University, Umeå, Sweden. Email:
<u>annasara.lenman@umu.se</u> or Prof. Anna K Överby Department of Clinical Microbiology,
Umeå University, Umeå, Sweden. Email: <u>anna.overby@umu.se</u>

Author contributions: U.H., E.R., C.A., A.B., A.K.Ö and A.Le designed the study. U.H., E.R.,
J.L, M.H., E.N., U.A. and A.Le conducted experiments and analyzed the results. T.B, B.Ö L.D.,
M.F., A.SS., A.La., M.K, S.C., J.N and A.E. performed inclusion and sampling of patients,
collected, managed, and analyzed clinical data. J.H. analyzed transcriptomics data. U.H., A.E,
C.A., A.B., A.K.Ö., and A.Le. wrote the manuscript with input from all authors.

36

This study was supported by: the Swedish Heart-Lung Foundation (20200385 to A.K.Ö & 37 38 A.L., 20200325 & 20210078 to C.A., and 20200366 & 20210049 to A.B.), SciLife Lab COVID-19 research program funded by the Knut and Alice Wallenberg Foundation (2020.0182 39 & C19R:028 to A.K.Ö. & A.L., and VC-2020-0015 to C.A.), Kempestiftelserna (grant no. JCK-40 1827 to A.K.Ö.), Umeå University and County Council of Västerbotten (#RV-938855 to C.A. 41 and #RV-970074 to A.K.Ö.), Carl Bennet AB (A.L.), the Fundraising Foundation for Medical 42 43 Research, Umeå University (978018 to A.L. and 964781 to U.H.), Nyckelfonden Örebro (OLL-938628, OLL-961416 to S.C.), Regional Research Council Mid Sweden (RFR-968856, RFR-44 940474 to S.C), the Swedish Research Council (2020-06235 to M.N.E.F, 2016-06514 to J.N., 45 2021-06602 to J.H.), J.N. is a Wallenberg Centre for Molecular Medicine Associated 46 Researcher. Computations were performed using resources provided by SNIC through Uppsala 47 Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project SNIC 48 2021/22-697 to J.H. Apart from funding, the sponsors were not involved in performing the 49 present study. 50

#### 51 ABSTRACT

52 **Background:** We have previously shown that lungs from deceased COVID-19 patients are 53 filled with hyaluronan (HA). In this translational study, we investigated the role of HA in all 54 stages of COVID-19 disease, to map the consequences of elevated HA in morbidity and identify 55 the mechanism of SARS-CoV-2-induced HA production.

56 Methods: Lung morphology was visualized in 3D using light-sheet fluorescence microscopy. HA was verified by immunohistochemistry, and fragmentation was determined by gas-phase 57 electrophoretic molecular mobility analysis. The association of systemic HA in blood plasma 58 and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, 59 WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS 6-9), during the acute and convalescent 60 phases and related to lung function. In vitro 3D-lung models differentiated from primary human 61 bronchial epithelial cells were used to study effects of SARS-CoV-2 infection on HA 62 metabolism. 63

Findings: Lungs of deceased COVID-19 patients displayed reduced alveolar surface area compared to healthy controls. We verified HA in alveoli and showed high levels of fragmented HA both in lung tissue and aspirates. Systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence and associated with reduced diffusion capacity. Transcriptomic analysis of SARS-CoV-2-infected lung models showed dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Corticosteroid treatment reduced inflammation and, also, downregulated HA synthases.

Interpretation: We show that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment. SARS-CoV-2 infection triggers a dysregulation of HA production, leading to increased concentrations of HA that are partially counteracted by corticosteroid treatment. Treatments directly targeting

- 75 HA production and/or degradation can likely be used early during infection and may alleviate
- 76 disease progression and prevent long-term lung complications.

#### 77 INTRODUCTION

78 The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hitherto caused more than 6.8 million reported deaths globally (by March 22, 2023, 79 according to WHO). The clinical manifestations of COVID-19 range from asymptomatic or 80 81 mild disease with symptoms from the upper respiratory tract to severe pneumonitis with acute respiratory distress syndrome (ARDS) and multiorgan failure. Several pathophysiological 82 mechanisms have been described as contributing to respiratory failure in COVID-19, including 83 hyperinflammation with disturbed coagulation, leading to disseminated pulmonary 84 microthrombi as well as diffuse alveolar damage, alveolar septal fibrous proliferation and 85 86 pulmonary consolidation (1, 2).

87

Hyaluronan (HA) is a glycosaminoglycan that constitutes an important structural component of 88 89 the extracellular matrix in tissues. Through interactions with cell-surface receptors, HA also regulates cellular functions, such as cell-matrix signaling, cell proliferation, angiogenesis and 90 cell migration (3). HA is often present in its high molecular weight structure in healthy tissue 91 and has an anti-inflammatory effect (4). In contrast, low molecular weight HA has been shown 92 93 to have a pro-inflammatory effect when HA fragments bind to toll-like receptors and induce 94 NF- $\kappa$ B signaling (5). HA also influences the development of fibrosis by affecting fibroblast proliferation, differentiation, and motility (6). 95

96

97 In addition, HA has a very high water-binding capacity, with the ability to occupy large 98 hydrated volumes up to 1,000 times its molecular mass, which can promote edema formation 99 (3). Accumulation of HA is associated with ARDS (7), and recent publications have shown 100 increased levels of HA in the lungs of deceased COVID-19 patients (8, 9) as well as elevated 101 plasma levels of HA in severe cases (10, 11). Anti-inflammatory treatment with the

102 corticosteroid dexamethasone results in lower mortality amongst hospitalized COVID-19 103 patients (12). Corticosteroids are known to be effective in reducing HA levels in other 104 inflammatory syndromes (13, 14), thus, clearance of HA may be critical in disease resolution 105 following COVID-19 (8). We recently found that severe COVID-19 is an important risk factor 106 for impaired respiratory function, characterized by a decrease in diffusion capacity (DL<sub>CO</sub>), 3-107 6 months after the infection (15). However, if the lung function correlates with systemic HA is 108 currently not clear.

109

Here we set out to investigate HA at all stages of COVID-19 disease, from acute infection to convalescence in mild, severely ill and fatal cases. Our aim was to understand molecular mechanisms involved in the pathological overproduction of HA in disease and pathogenicity. In addition, we established an *in vitro* 3D-lung model to investigate the impact of SARS-CoV-2 infection on HA metabolism as well as the role of corticosteroid treatment to define molecular disease mechanisms.

116

117 **RESULTS** 

# Morphological differences induced by COVID-19 visualized by light sheet fluorescent microscopy.

We have previously shown that the lungs of fatal COVID-19 patients are filled with HA (8). However, it is not clear which consequences HA has on the structural integrity of the lung and the alveolar volume. To address this, we set out to morphologically determine the threedimensional organization within lung biopsies with light sheet fluorescence microscopy (LSFM). These biopsies originated from three deceased COVID-19 patients, four healthy donors who underwent lung resection, and one patient who underwent lung resection ten weeks post intensive care treatment due to severe COVID-19 infection, here referred as recovered.

The lung biopsies were processed, cleared and subjected to LSFM visualizing the 127 128 autofluorescence (figure 1A). Major differences in the morphology of the lung were detected by maximum intensity projection (figure 1B-D, supplementary figure 1, and supplementary 129 movie 1-3). The lungs of fatal COVID-19 patients were considerably denser compared to the 130 healthy controls and recovered lung. Optical sections of the tissue revealed thin alveolar walls 131 in the controls and recovered, whereas the distances between the alveoli in COVID-19 lungs 132 were larger (figure 1E-G). The size distribution of the alveoli diameter was also smaller in the 133 COVID-19 compared to control and recovered lung (figure H). The number of empty alveoli 134 was fewer in the COVID-19 lungs as visualized in the surface rendering of the alveolar space 135 136 (figure 1I-K). Next, the surface of the alveoli was quantified to better understand the capacity of the gas exchange in the samples. The isosurfaces of the alveoli were determined and showed 137 a major loss of alveoli surface in the COVID-19 lungs compared to the healthy controls (figure 138 1L). Worth noting is that the lung morphology found in the recovered COVID-19 patient 139 showed high similarity to the healthy controls. 140

141

To confirm the presence of HA in alveoli and to see if there is a difference in accumulation between the upper and lower lung lobes, histochemistry was performed on five COVID-19 necropsies (figure 2A-B). We did not observe a major difference between patients or lung regions, but extensive accumulation of HA was seen in COVID-19 necropsy compared to healthy controls (figure 2C). Collagen coils, a marker for irreversible lung damage, were also found in large areas of the necropsy where no remains of alveolar walls could be detected (figure 2C).

149

150

151

#### 152 Severe COVID-19 induces fragmentation of HA in lung tissue and aspirates

153 As fragmented low molecular HA increases at sites of active inflammation and display a proinflammatory activity, HA fragmentation likely contributes to disease progression of 154 COVID-19. HA was extracted from necropsies derived from the upper, and lower left lobe of 155 five COVID-19 patients to investigate this. The isolated HA was subjected to size determination 156 157 analysis by gas-phase electrophoretic mobility molecular analysis (GEMMA). Both the upper 158 and lower lung lobes displayed highly fragmented HA (figure 2D). Although we did not observe an apparent difference in the abundance of HA with histochemistry between the upper and 159 lower lung lobes (figure 2B), we found higher levels of both total HA and fragmented HA in 160 161 the lower parts of the lung with GEMMA (figure 2D, area under the curve). Since fragmented HA induces a proinflammatory state and initiates migration of immune cells (16), we analysed 162 the presence of neutrophils in lungs by staining for elastase. We detected major neutrophil 163 164 infiltration in COVID-19 lungs compared to uninfected controls (supplementary figure 2). Next, nasopharyngeal aspirates (NPA) and endotracheal aspirates (ETA) collected from three 165 COVID-19 patients were analysed to investigate the fragmentation process of HA during 166 ongoing severe disease. All patients displayed fragmented HA, however, in contrast to the 167 168 fragmentation in the necropsy samples, there were large individual variations between the total 169 amount and degree of fragmentation (figure 2E-F). The finding that HA accumulated in the lungs and aspirates of severely diseased patients prompted us to measure the systemic levels of 170 HA. We performed this in a cohort of mild and severely ill patients during acute disease and 171 172 convalescence. Our objective was to investigate if plasma concentrations of HA could be used as a biomarker for disease severity. 173

174

175

#### Hyaluronan levels in plasma increase in severe COVID-19 and correlate with a reduction 176

#### 177 in lung function at follow up

Patients with COVID-19 infection classified as severe, based on requirement of high-flow nasal 178 oxygen treatment and/or admission to the intensive care unit (ICU) corresponding to WHO-179 CPS 6-10 (17), were matched according to age to patients with mild COVID-19 (WHO-CPS 1-180 5). In total 103 individuals were selected; 37 patients were classified as severe and 66 patients 181 as mild. The demography and clinical characteristics are presented in table 1. The groups 182 differed significantly in BMI, obesity, minimum levels of hemoglobin, maximum levels of C-183 reactive protein, white blood cell count, and neutrophil count. No significant differences were 184 185 observed when it came to comorbidities at baseline. Thirty-two (86.5%) patients in the severe group and four (6.1%) in the mild group received corticosteroid treatment (p < 0.001). Most of 186 these patients, 28 in the severe and two in the mild group, received the first dose before the first 187 188 sampling timepoint.

189

The concentration of HA in plasma samples was determined using ELISA in order to assess the 190 association between HA and disease severity. A general increase in HA concentrations was 191 192 observed in samples taken during the acute phase of the disease in both patients with mild and severe COVID-19, as compared to healthy controls (figure 3A). The HA concentrations were 193 even further increased in patients with severe COVID-19. Interestingly, although HA 194 195 concentrations declined in the convalescent phase (mild p < 0.0001, severe p < 0.0001), they remained elevated compared to healthy controls, especially in patients with severe disease. A 196 sex comparison of HA plasma concentrations in the acute phase showed a similar increase in 197 198 HA in severe COVID-19 in women and men (figure 3B). However, the HA levels remained 199 higher among women compared to men (p=0.043, data not shown) in the convalescent phase of mild COVID-19. Analyses assessing the impact of age showed an increase in HA 200

concentrations in severe compared to mild COVID-19 in both older (60-89 years) and younger 201 202 (18-59 years) patients, with a general trend towards higher HA concentrations in the older age group (mild disease: p=0.01, severe disease: p=0.17) (figure 3C). As we have seen that HA 203 accumulated in the lungs during COVID-19, and systemic levels of HA remains high even after 204 12 weeks, we next wanted to investigate how the systemic HA levels would correlate to actual 205 206 lung function. HA levels of acutely infected patients were associated with the percentage of 207 predicted diffusion capacity (DL<sub>CO</sub>% pred) three to six months after infection (figure 3D-G). Lung function measurements were available in 70 out of 103 patients. The analysis was adjusted 208 209 for sex, chronic lung disease, cardiovascular disease, hypertension, diabetes, smoking (current 210 or previous), obesity (BMI ≥30), severity of COVID-19 (mild or severe), and age (20-59 and 60-89 years). Our results showed a negative correlation between HA levels in both the 211 convalescent phase and acute phase with DL<sub>CO</sub>% pred (supplementary table 1 and 2). 212

213

In summary, plasma concentrations of HA were substantially increased in COVID-19 patients and correlated to disease severity and reduced diffusion capacity. We then performed infection experiments in a human 3D-lung model to further study the potential mechanisms behind the increase of HA in COVID-19.

218

# SARS-CoV-2 infection causes an inflammatory response, which is counteracted by corticosteroids in a human 3D-lung model

We used a lung model that closely resembles the human respiratory tract based on primary human bronchial epithelial cells (HBECs) isolated from human donors. This model was used to characterize the cellular pathways affected by SARS-CoV-2 infection and the effects of corticosteroid treatment with respect to inflammation and HA metabolism. The cells were differentiated at an air-liquid interface (ALI) to form a polarized epithelium containing an apical

layer of fully functional secretory and ciliated cells and an underlying layer of basal cells (18). 226 227 The lung cultures were treated with, or without, the corticosteroid betamethasone, and infected with SARS-CoV-2 (figure 4A). The course of infection was monitored daily by collection of 228 229 apical secretions containing released progeny virus and the viral load was quantified by qPCR. A distinct increase in viral RNA was observed over time, indicating an active viral replication 230 231 in the HBEC ALI-cultures (figure 4B). Betamethasone-treated cultures showed reduced levels 232 of released progeny virus. The infected HBEC ALI-cultures were harvested at 96h post infection and subjected to total RNA sequencing, to identify the mechanisms and pathways 233 regulated by SARS-CoV-2 infection and betamethasone treatment. Statistical comparison of 234 235 genes expressed in uninfected vs. infected HBEC ALI-cultures (figure 4C, supplementary table 3) identified 167 differentially expressed genes (DEGs) that were upregulated upon SARS-236 CoV-2 infection, with a strong enrichment of genes involved in the immune response, 237 238 especially type I interferon (IFN-I) signaling. A similar statistical comparison of infected HBEC ALI-cultures with or without betamethasone treatment was performed to evaluate the effect of 239 betamethasone treatment. This identified 102 genes that were upregulated, and 229 genes that 240 were downregulated in the betamethasone-treated cultures (figure 4D, supplementary table 3). 241 Interestingly, 73 of the 167 genes upregulated by infection (figure 4C) were downregulated by 242 243 betamethasone treatment (figure 4D). A heatmap displaying the mean expression values of the individual overlapping genes showed a clear upregulation of these genes by SARS-CoV-2 244 infection, which was counteracted by betamethasone treatment (figure 4E). Several of the 245 affected genes were involved in inflammatory responses, correlating well with the anti-246 inflammatory activity of betamethasone. We also collected basolateral samples from the HBEC 247 248 ALI-cultures at 96h post infection and analyzed these with a targeted cytokine panel based on proximity extension assay, allowing a quantitative concentration measurement of each cytokine 249 (figure 4F). Of the ten cytokines that showed significant changes, eight were downregulated by 250

betamethasone treatment, but not affected by the infection. CXCL10 and CXCL11 were both
upregulated by the SARS-CoV-2 infection and subsequently downregulated by steroid
treatment.

254

# 255 SARS-CoV-2 affects HA metabolism by upregulation of HA synthases and 256 downregulation of hyaluronidases

257 To further investigate the direct effect of SARS-CoV-2 on HA synthesis and degradation, expression levels of the three human hyaluronan synthases, HAS1, HAS2 and HAS3 and the two 258 major hyaluronidases, HYAL1 and HYAL2, were determined in HBEC ALI-cultures from two 259 260 different donors five days post infection. No effect was seen on HAS1 expression, but SARS-CoV-2 infection increased HAS2 in donor 2 and HAS3 expression in both donors (figure 4G-I). 261 Betamethasone treatment of infected cultures resulted in a reduction of the upregulated HAS2 262 263 expression in donor 2 and HAS3 in donor 1 (figure 4H and I). Additionally, SARS-CoV-2 infection decreased expression of hyaluronidase HYAL1 in both donors and HYAL2 in donor 2 264 (figure 4J and K). The hyaluronidase genes were not significantly affected by betamethasone 265 treatment (figure 4J and K). Both upregulation of HA synthases and downregulation of 266 267 degrading hyaluronidases can induce an increase in HA concentrations. Indeed, measurements 268 of HA concentrations in the apical secretions from HBEC ALI-cultures confirmed the transcriptional changes with an increase in HA in cultures infected by SARS-CoV-2, which 269 were kept at baseline concentrations when simultaneously treated with betamethasone (figure 270 271 4L).

272

Taken together, our results identified genes involved in viral defense and inflammation affected
by SARS-CoV-2 infection. Betamethasone treatment demonstrated a general counteraction
against the viral transcriptional effect. SARS-CoV-2 infection and betamethasone treatment

also affected genes with potential impact on HA production and degradation. In addition to the 276 277 effects on HA synthases and hyaluronidases, we observed an upregulation of transcription factors early growth response 1 and 2 (EGR1, 2) upon SARS-CoV-2 infection and a 278 downregulation of lactate dehydrogenase A (LDHA) and TP53 induced glycolysis regulatory 279 280 phosphatase (TIGAR) after betamethasone treatment, all of which are involved in the glycolysis and therefore affect HA metabolism (supplementary table 3). Based on our results, we present 281 a model where the positive action of betamethasone in severe COVID-19 patients is a combined 282 action of a reduced inflammatory response (figure 5A, supplementary table 3) and a reduction 283 of the pathological overproduction of HA upon SARS-CoV-2 infection (figure 5B, 284 285 supplementary table 3).

286

#### 287 **DISCUSSION**

We have previously shown that lungs from deceased COVID-19 patients are filled with a clear liquid jelly consisting of HA, which impairs the capillary-alveolar gas exchange and leads to respiratory failure. In this study, we investigated the morphology of the lung in 3D, the presence of fragmented HA during severe COVID-19 and the correlation between systemic HA levels and diffusion capacity of the lungs after recovery. We also show the mechanisms behind the pathological increase in HA levels, which were counteracted by corticosteroid treatment, to possibly identify new therapeutic targets using a human *in vitro* 3D-lung model.

295

Morphological studies of tissue are commonly done by immunohistochemistry of thin tissue slices. These have the advantage of a high resolution down to subcellular level, and many cellular markers can be used to identify different features. However, it is much more difficult to analyze the composition and morphology of lung tissue especially the alveolar volume or surface areas. We therefore used LSFM to study the morphology of lung necropsies and

biopsies in 3D. Our results showed a reduction in the number and size of the alveoli, as well as 301 302 the surface area used for gas exchange at end stage of COVID-19 compared to healthy controls. 303 Interestingly, LSFM has been used previously in a ferret model of COVID-19, but no similar obstructions were seen in their lungs (19). With histochemistry we showed that the alveoli were 304 filled with HA and this HA was highly fragmented in the COVID-19 necropsies, likely 305 contributing to the inflammatory milieu visualized by large infiltrates of neutrophils. The HA 306 307 was also fragmented in severe COVID-19 in both nasopharyngeal and endotracheal aspirates. Interestingly, hyper-induction of HA in the lungs appears in many respects to be a reversible 308 process. Even though reduced diffusion capacity correlates to disease severity (15) and is 309 310 related to severity of radiologic lung involvement at admission (20), there is still restitution. 311 This is supported by our data where the recovered COVID-19 patient did not present with a reduced mean alveolar surface area compared to the healthy controls. However, the presence of 312 313 collagen coils that disrupt alveolar walls in necropsy COVID-19 lungs suggests that the filling of HA in the alveoli precedes the development of collagen fibrosis and irreversible lung 314 damage. This is supported by previous findings in both human inflammatory diseases and in a 315 lung damage rat model (6, 21, 22). The role of HA size in fibrosis is not clear, but it has been 316 317 demonstrated that the interaction of fragmented HA and the receptor HA-mediated motility 318 receptor (RHAMM), increased the infiltration of fibroblasts, leading to uncontrolled wound healing with collagen production and fibrosis (23). 319

320

We showed that despite an overall reduction in systemic HA concentrations during the convalescent phase ( $\geq$ 12 weeks), the plasma levels did not normalize in either mild or severe COVID-19 patients and remained significantly higher compared to the control group. Prior studies have demonstrated an elevation of HA concentration associated with disease severity in the acute phase of COVID-19 (10, 11), but the long-term consequences of COVID-19 on HA

levels have not previously been thoroughly investigated. The tissue half-life of HA ranges from half a day to two-three days, and the half-time in blood is even shorter (24). The sustained elevation of plasma HA concentrations demonstrated here therefore suggests an imbalance in the production and degradation of HA that remains for at least 12 weeks after disease onset, even after mild disease. The correlation of high plasma levels of HA in both acute and convalescent phase with reduced diffusion capacity also implies that plasma HA may be used as a predictive biomarker for future lung function impairment.

333

The molecular mechanisms behind the observed increase in HA synthesis upon SARS-CoV-2 334 335 infection remain to be clarified. Based on the results of this study, we here propose a model in which SARS-CoV-2 infection causes transcriptional changes of genes involved in HA 336 metabolism, which are partially counteracted by corticosteroid treatment. In our human in vitro 337 338 3D-lung model, SARS-CoV-2 infection caused an upregulation of the transcription factors EGR1 and EGR2, which in turn activated the expression of HA synthases HAS2 and HAS3. At 339 the same time, SARS-CoV-2 infection decreased the degrading hyaluronidases. However, it is 340 possible that additional pathways can affect HA production. It was recently shown that specific 341 342 RNA sequences in the SARS-CoV-2 genome can activate expression of HAS2 and, 343 consequently, increase HA synthesis (25). In addition, changes to the glycolysis pathway may affect HA levels, due to an increased production of HA precursor molecules (26). Interestingly, 344 others have shown that SARS-CoV-2 infection and subsequent replication induce an increased 345 346 glucose metabolism in infected cells (27, 28). Corticosteroid treatment reduced the overall HA concentration in our 3D-lung model during SARS-CoV-2 infection. Interestingly, besides 347 counteracting the SARS-CoV-2-induced effect on hyaluronan synthases, corticosteroid 348 treatment of the infected 3D-lung model also decreased the expression of lactate dehydrogenase 349

350 A (LDHA) and TIGAR, which may both contribute to decreased HA production via the 351 glycolysis pathway (29, 30).

352

Today, one of the few evidence-based treatment options for patients with severe to critical 353 COVID-19 is corticosteroids (12). However, the timing of treatment seems to be crucial. Early 354 treatment of COVID-19 patients with corticosteroids has been shown to have less positive effect 355 356 than treating severely ill patients (12). The increased levels of HA in the blood from both mild and severe cases of COVID-19, shown by us and others (10, 11), indicate a dysregulated HA 357 metabolism in COVID-19, which was also supported by the findings in our 3D-lung model. 358 359 Hyaluronan production and/or degradation therefore poses an attractive treatment target for 360 severe COVID-19. Hymecromone, an FDA-approved drug for treatment of biliary spasm, has a more direct action against HA synthesis and could be used to specifically treat the 361 362 overproduction of HA. Such a high-precision treatment could avoid some of the negative effects of corticosteroids and enable treatment at an earlier stage to prevent disease progression. A 363 recent clinical trial with hymecromone showed efficient inhibition of COVID-19 progression 364 and warrants further investigations (31). 365

366

367 In summary, our results showed destructed lung morphology with markedly decreased gas exchange surface in COVID-19, fragmented inflammatory HA in both nasopharyngeal aspirate 368 and endotracheal aspirate and sustained increased levels of HA in peripheral blood in COVID-369 19 patients. The increased HA expression could be explained by the mechanisms identified in 370 our *in vitro* lung model including an imbalance in HA production and degradation induced upon 371 372 SARS-CoV-2 infection. We also show that elevated systemic HA levels both in acute COVID-19 and convalescence phase negatively correlate with diffusion capacity in the lungs during 373 convalescence. Further studies are needed to evaluate systemic HA as a biomarker for long term 374

lung function impairment. We show that HA is an important factor in COVID-19 pathogenesis,
and studies on targeting HA metabolism as an alternative or complementary treatment to
corticosteroids to reduce the acute and long-term health consequences of COVID-19 are
warranted.

379

#### 380 METHODS

#### 381 Tissue pre-processing for optical 3D-imaging

Lung biopsies from four healthy controls, three deceased COVID-19 patients and one patient 382 that recovered from COVID-19 were washed in PBS, fixed in formalin overnight, dehydrated 383 384 successively into methanol (MeOH) (25%, 50%, 75%, 100%, 15 min each step) and stored at - $20^{\circ}$ C until use. Prior to clearing, the lung samples were treated in bleaching solution (H<sub>2</sub>O<sub>2</sub>: 385 dimethyl sulfoxide: MeOH, 3:1:2) overnight at room temperature (RT). The bleaching solution 386 387 was refreshed, and the samples were incubated for an additional 6 hours at RT. Following bleaching, the samples were rehydrated into PBS (25%, 50%, 75%, 100%, 15 min each step) 388 and mounted in 1.5% low-melting point agarose (Lonza<sup>TM</sup> SeaPlaque<sup>TM</sup> Agarose, Lonza, USA). 389 After solidifying overnight, the agarose pieces were cut into cuboids and dehydrated into MeOH 390 (25%, 50%, 75%, 100%, 15 min each step). The samples were subsequently washed in MeOH 391 392 for 2x24 hours on rotation in order to remove any residual water. Following MeOH washes, the samples were optically cleared in BABB (benzyl alcohol, benzyl benzoate, 1:2) changing 393 solution every 12 hours until the biopsies were completely cleared. 394

395

#### 396 Light sheet fluorescence microscopy and 3D image processing

High resolution 3D images of the lungs were acquired using a UltraMicroscope II (Miltenyi
Biotec, Germany) fitted with an 1x Olympus objective (Olympus PLAPO 2XC) and a lens
corrected dipping cap MVPLAPO 2x DC DBE objective attached to an Olympus MVX10 zoom

body with a 3000 step chromatic correction motor. The lung regions of interest were captured 400 401 at a magnification of 1.6x with a scan depth of 1000 µm, a dynamic focus range across the specimen capturing 10 images per section, and a step-size of 5 µm yielding a voxel size of 1.89 402 x 1.89 x 5  $\mu$ m. The samples were scanned for autofluorescence with the filters: Ex 470/40, Em: 403 525/50 using an exposure time of 300ms. Optical sections were saved in \*ome.tif format native 404 405 to the ImspectorPro software (version 7.0.124.9 LaVision Biotex GmbH, Germany). The 406 \*ome.tif files were converted into 3D projection \*ims files using the Imaris file converter (version 9.9.1, Bitplane, UK) 3D volumes were generated using the built in surfacing method 407 of Imaris (version 9.8.0, Bitplane, UK). To quantify the "empty space volume", roughly 408 409 translating to the alveolar volume, the threshold was set to only include hypointense space using absolute intensity for surfacing, with a surface grain size set to 0.8 µm. Further, an exclusion 410 filter removing objects consisting of less than 10 voxels was applied to remove general noise. 411 412 The anatomy surface was generated and set to include all signal above the hypointense signal with a surface grain size of 3.78 µm and a 10 voxel exclusion filter. Surfaces generated from 413 hypointense regions outside the tissue volume were manually excluded when possible. 414 Volumes and area of the segmented surfaces were extracted from Imaris as Excel (Microsoft, 415 Office 365, version 2301) \*.XML file format for quantification. 416

417

#### 418 Isolation and fragmentation of HA from lung biopsies and aspirates

419 *(i)* HA isolation

420 Cellular secrets were dried in a Savant SpeedVac DNA 110 vacuum concentrator (Thermo 421 Fisher Scientific, MA, USA). Proteins and nucleic acids were digested with proteinase K 422 (Sigma-Aldrich, St Louis, MO, USA) and benzonase nuclease (Sigma-Aldrich) on two 423 consecutive days. At the end of each digestion, chloroform was added to each sample and the 424 extracted aqueous phase was solvent exchanged to 0.1 M NaCl using Amicon Ultra 3K

425 concentration units (Millipore, Billerica, MA, USA) followed by overnight precipitation in 99%
426 ethanol. Sulphated glycosaminoglycans and remaining non-HA contaminants were removed
427 with anion-exchange mini spin columns (Thermo Fisher Scientific, MA, USA), based on NaCl
428 binding. Finally, to remove salt the sample was solvent exchanged to 20 mM ammonium acetate
429 (pH 8.0) in Amicon Ultra 3K concentration units.

430

431 *(ii) HA molecular mass analysis* 

HA mass analysis was undertaken using a gas-phase electrophoretic mobility molecular
analysis (GEMMA) (TSI Corp., MN, USA). The molecule diameter analyzed in the GEMMA
was converted to molecular mass by analyzing HA standards ranging from 30 kDa to 2500 kDa
(Hyalose, OK, USA). The area under the curve corresponds to the number of molecules in the
GEMMA analysis.

437

#### 438 Study design and study population

Data and clinical samples were obtained from the CoVUm study, a prospective, multicenter 439 observational study of COVID-19 including patients from Umeå and Örebro, and coordinated 440 from Umeå University, Sweden (www.clinicaltrials.gov identifier NCT 04368013). The study 441 442 protocol and cohort have been described in detail earlier (32). Non-hospitalized patients aged  $\geq$ 15 years and hospitalized patients aged  $\geq$ 18 years with a positive PCR-test for SARS-CoV-2 443 were enrolled in the study. Written informed consent was obtained from all participants or their 444 445 next of kin before the first sampling timepoint. At data export on May 4, 2022, a total of 543 participants, enrolled between 27 April 2020 and 28 May 2021, had been registered in the 446 447 CoVUm database. Seven of the participants were excluded since they did not fulfill the inclusion criteria (false positive PCR-tests for SARS-CoV-2). Out of the remaining 536 448 participants, all patients classified as severely ill during the acute phase of the disease, and with 449

available blood samples, were selected for this study. In addition, 66 patients with mild COVID-450 451 19 were selected from the remaining study cohort. Participants were classified as "severe" if they required high-flow nasal oxygen treatment (HFNO) and/or was admitted to the intensive 452 care unit (ICU) during the acute phase of illness, corresponding to WHO Clinical Progression 453 Scale (WHO-CPS) 6-10 (17). All other participants were classified as "mild", corresponding to 454 WHO-CPS 1-5. Blood samples were obtained at acute phase (0-4 weeks after onset) and 455 456 convalescent phase ( $\geq 12$  weeks). For study outline, see figure 2A. A healthy control group, consisting of plasma samples collected from anonymous blood donors was included for 457 reference. The study was performed according to the Declaration of Helsinki and approved by 458 459 the Swedish Ethical Review Authority.

460

#### 461 Data collection and clinical samples

462 All clinical metadata including age, sex, Charlson Comorbidity Index (CCI) (33), tobacco use, medication at enrollment, body mass index, type of respiratory support and medical treatment 463 were collected and managed using the REDCap electronic data capture tools hosted at Umeå 464 University (34, 35). Clinical chemistry data of conventional inflammatory markers were 465 extracted retrospectively from the patients' electronic medical records. The highest and lowest 466 467 values of each biomarker from each individual, during the first 180 days after symptom onset were extracted for further analysis. Plasma samples used for HA analysis were collected at each 468 timepoint in 6 ml EDTA tubes (BD Diagnostics). 469

470

#### 471 Measurement of hyaluronan concentration in plasma samples

Plasma hyaluronan (HA) concentrations were measured with a competitive HA-binding
protein-based enzyme-linked immunosorbent assay (ELISA)-like concentration measurement
kit (K-1200; Echelon Biosciences Inc., Salt Lake City, UT, USA), according to the

475 manufacturer's instructions. Samples were run in duplicate and a coefficient of variation (CV)
476 < 10% was considered acceptable. Absorbance was measured on a ThermoMultiskan Ascent</li>
477 (Thermo Fisher Scientific, MA, USA) and plotted by polynomial regression against the
478 concentration of the standard curve.

479

#### 480 Lung function tests

Lung function tests were conducted 3-6 months after study enrolment for non-hospitalized
patients, or discharge from hospital for patients hospitalized during the acute phase of illness,
as previously described (15). Reference values for DL<sub>CO</sub> were calculated using The Global Lung
Function Initiative (GLI) Network guidelines.

485

# 486 Assessment of hyaluronan metabolic pathways upon SARS-CoV-2 infection in an *in vitro*487 3D-lung model

#### 488 *(i) Generation of the human primary 3D-lung model*

Primary human bronchial epithelial cells (HBEC) were isolated from proximal airway tissue 489 obtained with informed consent from two patients, who underwent thoracic surgery at the 490 University Hospital, Umeå, Sweden (ethical permission approved by the Regional Swedish 491 492 Ethical Review Authority in Umeå). HBECs were grown and differentiated at an air-liquid interface (ALI) forming an in vitro 3D-lung model as previously described (16). In short, 493 HBECs were grown and differentiated on 6.5 mm semipermeable transwell inserts (0.4 µm 494 495 Pore Polyester Membrane Insert, Corning) and after two weeks at air-liquid interface (ALI) the cultures reached full differentiation, which was assessed using light microscopy focusing on 496 epithelial morphology, presence of ciliated cells, and mucus production along with 497 immunofluorescence staining for ciliated cells (acetylated-tubulin, T6793, Sigma) and goblet 498 cells (muc5AC, Ab-1 (45M1), #MS-145-P, ThermoFisher). 499

#### 500 *(ii) Betamethasone treatment*

501 Fully differentiated HBEC-ALI cultures were either mock treated or treated with 502 betamethasone (Alfasigma) 20 h prior to infection by addition of 700  $\mu$ l fresh basal media 503 containing 0.3  $\mu$ M betamethasone. For study outline see figure 4A. Shortly before infection, 504 the basal media was exchanged once more and betamethasone was replenished in the treated 505 wells. Betamethasone was replenished every 24 h post infection.

#### 506 (iii) SARS-CoV-2 infection

507 clinical isolate SARS-CoV-2/01/human/2020/SWE (GeneBank The accession no. MT093571.1) was kindly provided by the Public Health Agency of Sweden. Vero E6 cells were 508 509 cultured in Dulbecco's modified Eagle's medium (DMEM, D5648 Sigma) supplemented with 5% FBS (HyClone), 100 U/mL penicillin and 100 µg/ml streptomycin (PeSt, HyClone) at 37°C 510 in 5% CO<sub>2</sub>. Propagation of the virus was done once in Vero E6 cells for 72 h and titration was 511 done by plaque assay. The apical side of the HBEC ALI-cultures were rinsed three times with 512 warm PBS shortly before infection.  $1.5 \times 10^4$  plaque forming units (PFU) of SARS-CoV-2 was 513 514 added to the apical compartment in a total volume of 100 µl infection medium (DMEM / PeSt), 515 corresponding to an approximate multiplicity of infection (MOI) of 0.05. The HBEC ALIcultures were incubated at 37°C and 5% CO<sub>2</sub> for 2.5 h before the inoculum was removed and 516 517 the cultures were washed with PBS to remove residual medium.

518 *(iv) Sample collection* 

Accumulated progeny virus and secretions were collected from the apical side of the HBEC ALI-cultures every 24 h by addition of 100  $\mu$ l warm PBS to the apical chamber followed by a 1 h incubation at 37°C and 5% CO<sub>2</sub>. The collected samples were stored at -80°C until RNA extraction. The progression of the infection was monitored for four days (96 h post infection).

523

#### 524 *(iv) Virus quantification by qPCR*

525 Viral RNA secreted from HBEC ALI-cultures was extracted from 50 µl of the apical samples using the QIAmp Viral RNA kit (Qiagen) following the manufacturer's instructions, and cDNA 526 was synthesized from 10 µl of eluted RNA. RT-qPCR for SARS-CoV-2 RNA was performed 527 in duplicates on a StepOnePlus<sup>TM</sup> Real-Time PCR System (Applied Biosystems) using the 528 529 **qPCRBIO** Probe Mix Hi-ROX (PCR biosystems) primers (Forward: and GTCATGTGTGGCGGTTCACT, Reverse: CAACACTATTAGCATAAGCAGTTGT) and 530 probe (CAGGTGGAACCTCATCAGGAGATGC) specific for viral RdRp. 531

532

#### 533 Transcriptomics, total RNA sequencing

At 96 h post infection the mock treated (n=3), infected (n=3) and infected + betamethasone 534 treated (n=3) HBEC ALI-cultures were washed three times on both sides with PBS. The HBEC 535 536 ALI-cultures were then lysed and RNA extraction was done using the NucleoSpin RNA II kit (Macherey-Nagel) following the manufacturer's instructions. RNA-seq libraries were prepared 537 using the Smart-seq2 method, and sequenced on an Illumina NextSeq 500 (75PE, v2.5 High 538 Output kit). STAR 2.7.1a was used to align the reads against a reference genome consisting of 539 540 GRCh38 and Sars\_cov\_2.ASM985889v3. A gene expression table was produced using 541 featureCounts (36). Differential expression analysis was performed using DESeq2 (37).

542

#### 543 **Cytokine quantification**

At 96 h post infection, samples were collected from the basal chambers of each of the HBEC ALI-cultures. The samples were inactivated with Triton X-100 at a final concentration of 1% followed by incubation at room temperature for 3 h. The levels of 45 cytokines were quantified by Proximity Extension Assay (Olink Target 48 Cytokine panel at Affinity Proteomics Uppsala,

548 SciLifeLab Sweden), which gives absolute (pg/mL) and relative (normalized protein 549 expression, NPX) concentration measurements of 45 pre-selected cytokines.

550

## 551 Quantification of HA synthases and hyaluronidases by qPCR

552 Total RNA from cells were extracted using the Nucleo-Spin RNA II kit (Macherey-Nagel). 1000 ng of RNA was used as input for cDNA synthesis using High-capacity cDNA Reverse 553 Transcription kit (Thermo Fisher). Cellular HA synthases (HAS1, 2 and 3) and hyaluronidases 554 555 (HYAL1 and 2) were quantified using qPCRBIO SyGreen mix Hi-ROX (PCR Biosystems) and QuantiTect primer (Qiagen, HAS1;QT02588509, HAS2;QT00027510, 556 assay HAS3;QT00014903, HYAL1;QT01673413, HYAL2;QT00013363) with actin as a housekeeping 557 gene (QT01680476) and run on a StepOnePlus<sup>TM</sup> Real-Time PCR System (Applied 558 Biosystems). 559

560

## 561 Measurement of HA concentration in apical secretions from HBEC ALI-cultures

Apical secretions from HBEC ALI-cultures were collected at 120 h post infection and HA
concentrations were measured with a Hyaluronic Acid AlphaScreen Assay (K-5800; Echelon
Biosciences Inc., Salt Lake City, UT, USA), according to the manufacturer's instructions.
AlphaScreen beads from the Histidine (Nickel Chelate) Detection Kit (PerkinElmer, MA, USA)
was used. Chemiluminescent emission was measured on a SpectraMax i3x (Molecular Devices,
CA, USA) and plotted by polynomial regression against the concentration of the standard curve.

568

#### 569 Statistical analysis

570 Statistical analysis was performed with Graphpad Prism 9 and Jamovi version 2.2.5 (The

571 jamovi project (2021)). jamovi (Version 1.6). Retrieved from <u>https://www.jamovi.org</u>).

572 Descriptive variables of the patient cohort were analyzed by Mann-Whitney U-test

573(continuous variables) and Fisher's exact test or Chi2 test (dichotomous variables). Missing574data were handled by complete case analysis. No correction for multiple testing was575performed. Multiple linear regression was used to explore the association between DL<sub>CO</sub> and576HA levels in plasma during the acute illness and the convalescent phase.Independent variables577were sex, chronic lung disease, cardiovascular disease, hypertension, diabetes, smoking578(current or previous), obesity (BMI  $\geq$ 30), severity of COVID-19 (mild or severe), and age579(20-59 and 60-89 years). The log transformation was used to address skewed data in HA.

580

## 581 Data availability

The CoVUm data cannot be made publicly available, according to Swedish data protection laws and the terms of ethical approval that were stipulated by the Ethical Review Authority of Sweden. Access to data from the CoVUm database is organized according to a strict data access procedure, to comply with Swedish law. For all types of access, a research proposal must be submitted to the corresponding authors for evaluation. After evaluation, data access is contingent on vetting by the Ethical Review Authority of Sweden, according to the Act (2003:460) concerning the Ethical Review of Research Involving Humans.

589

#### 590 Acknowledgement:

The authors thank the team at Affinity Proteomics Uppsala, SciLifeLab Sweden, for providing assistance with Olink assays. We acknowledge our study nurses Ida-Lisa Persson and Anna Kauppi at the Department of Infectious Diseases in Umeå and Christine Degner, Anna Segerås and Lena Irvhage in Örebro, and the personnel at the Clinical Research Center at Umeå University Hospital and Örebro University Hospital for enrolment and sampling of study participants. We also acknowledge Umeå Center for Microbial Research (UCMR); the Biochemical Imaging Center at Umeå University (BICU), and the National Microscopy

- 598 Infrastructure for microscopy support (NMI; VR-RFI 2019-00217). Figure 1A, 2A, 4A and 5
- 599 were created using BioRender.com.

#### 600 REFERENCES

- 1. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, 601 Kastritis E, Terpos E, Dimopoulos MA. Organ-specific manifestations of COVID-19 602 603 infection. Clin Exp Med 2020; 20: 493-506.
- 604 2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-605 606 19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420-607 422.
- 3. Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. 608 Immunol Cell Biol 1996; 74: A1-7. 609
- 4. Delmage JM, Powars DR, Jaynes PK, Allerton SE. The selective suppression of 610 611 immunogenicity by hyaluronic acid. Ann Clin Lab Sci 1986; 16: 303-310.
- 612 5. Petrey AC, de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol 2014; 5: 101. 613
- 614 6. Albeiroti S, Soroosh A, de la Motte CA. Hyaluronan's Role in Fibrosis: A Pathogenic Factor or a Passive Player? Biomed Res Int 2015; 2015: 790203. 615
- 7. Hallgren R, Samuelsson T, Laurent TC, Modig J. Accumulation of hyaluronan (hyaluronic 616 617 acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 682-687. 618
- 619 8. Hellman U, Karlsson MG, Engstrom-Laurent A, Cajander S, Dorofte L, Ahlm C, Laurent C, 620 Blomberg A. Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options? J Biol Chem 2020; 295: 15418-15422. 621
- 9. Kratochvil MJ, Kaber G, Demirdjian S, Cai PC, Burgener EB, Nagy N, Barlow GL, Popescu 622 623 M, Nicolls MR, Ozawa MG, Regula DP, Pacheco-Navarro AE, Yang S, de Jesus Perez VA, Karmouty-Quintana H, Peters AM, Zhao B, Buja ML, Johnson PY, Vernon RB, 624 Wight TN, Stanford C-BSG, Milla CE, Rogers AJ, Spakowitz AJ, Heilshorn SC, 625 Bollyky PL. Biochemical, biophysical, and immunological characterization of 626 respiratory secretions in severe SARS-CoV-2 infections. JCI Insight 2022; 7. 627
- 10. Ding M, Zhang Q, Li Q, Wu T, Huang YZ. Correlation analysis of the severity and clinical 628 prognosis of 32 cases of patients with COVID-19. Respir Med 2020; 167: 105981. 629
- 630 11. Donlan AN, Sutherland TE, Marie C, Preissner S, Bradley BT, Carpenter RM, Sturek JM, Ma JZ, Moreau GB, Donowitz JR, Buck GA, Serrano MG, Burgess SL, Abhyankar 631 632 MM, Mura C, Bourne PE, Preissner R, Young MK, Lyons GR, Loomba JJ, Ratcliffe SJ, Poulter MD, Mathers AJ, Day AJ, Mann BJ, Allen JE, Petri WA, Jr. IL-13 is a driver 633 of COVID-19 severity. JCI Insight 2021; 6. 634
- 12. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, 635 Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, 636 Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, 637 Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients 638 639 with Covid-19. N Engl J Med 2021; 384: 693-704.
- 13. Ernst G, Lompardia S, Cordo Russo R, Gentilini V, Venturiello S, Galindez F, Grynblat P, 640 Hajos SE. Corticosteroid administration reduces the concentration of hyaluronan in 641 642 bronchoalveolar lavage in a murine model of eosinophilic airway inflammation. Inflamm Res 2012; 61: 1309-1317. 643
- 14. Engstrom-Laurent A, Hallgren R. Circulating hyaluronate in rheumatoid arthritis: 644 relationship to inflammatory activity and the effect of corticosteroid therapy. Ann 645 Rheum Dis 1985; 44: 83-88. 646
- 15. Bjorsell T, Sundh J, Lange A, Ahlm C, Forsell MNE, Tevell S, Blomberg A, Edin A, 647 Normark J, Cajander S. Risk factors for impaired respiratory function post COVID-19: 648


649 A prospective cohort study of nonhospitalized and hospitalized patients. J Intern Med 650 2023. 651 16. Khan AI, Kerfoot SM, Heit B, Liu L, Andonegui G, Ruffell B, Johnson P, Kubes P. Role of CD44 and hyaluronan in neutrophil recruitment. J Immunol 2004; 173: 7594-7601. 652 653 17. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure 654 set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192-e197. 18. Rosendal E, Mihai IS, Becker M, Das D, Frangsmyr L, Persson BD, Rankin GD, Groning 655 R, Trygg J, Forsell M, Ankarklev J, Blomberg A, Henriksson J, Overby AK, Lenman 656 657 A. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections. 658 mBio 2022: e0089222. 19. Zaeck LM, Scheibner D, Sehl J, Muller M, Hoffmann D, Beer M, Abdelwhab EM, 659 Mettenleiter TC, Breithaupt A, Finke S. Light Sheet Microscopy-Assisted 3D Analysis 660 of SARS-CoV-2 Infection in the Respiratory Tract of the Ferret Model. Viruses 2021; 661 662 13. 20. Truffaut L, Demey L, Bruyneel AV, Roman A, Alard S, De Vos N, Bruyneel M. Post-663 664 discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission. Respir Res 2021; 22: 29. 665 21. Bjermer L, Lundgren R, Hallgren R. Hvaluronan and type III procollagen peptide 666 667 concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 1989; 44: 126-131. 668 22. Hernnas J, Nettelbladt O, Bjermer L, Sarnstrand B, Malmstrom A, Hallgren R. Alveolar 669 670 accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat. Eur Respir J 1992; 5: 404-410. 671 23. Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, Winnik F, Savani 672 673 R, Bagli DJ, Luyt LG, Cowman MK, McCarthy JB, Turley EA. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in 674 excisional skin wounds. Am J Pathol 2012; 181: 1250-1270. 675 24. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and 676 turnover. J Intern Med 1997; 242: 27-33. 677 25. Li W, Yang S, Xu P, Zhang D, Tong Y, Chen L, Jia B, Li A, Lian C, Ru D, Zhang B, Liu 678 M, Chen C, Fu W, Yuan S, Gu C, Wang L, Li W, Liang Y, Yang Z, Ren X, Wang S, 679 Zhang X, Song Y, Xie Y, Lu H, Xu J, Wang H, Yu W. SARS-CoV-2 RNA elements 680 share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer 681 network. EBioMedicine 2022; 76: 103861. 682 683 26. Hascall VC, Wang A, Tammi M, Oikari S, Tammi R, Passi A, Vigetti D, Hanson RW, Hart GW. The dynamic metabolism of hyaluronan regulates the cytosolic concentration of 684 685 UDP-GlcNAc. Matrix Biol 2014; 35: 14-17. 686 27. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, Prodonoff JS, Carregari VC, de Biagi Junior CAO, Crunfli F, Jimenez Restrepo JL, 687 Vendramini PH, Reis-de-Oliveira G, Bispo Dos Santos K, Toledo-Teixeira DA, Parise 688 689 PL, Martini MC, Marques RE, Carmo HR, Borin A, Coimbra LD, Boldrini VO, Brunetti NS, Vieira AS, Mansour E, Ulaf RG, Bernardes AF, Nunes TA, Ribeiro LC, Palma AC, 690 Agrela MV, Moretti ML, Sposito AC, Pereira FB, Velloso LA, Vinolo MAR, Damasio 691 692 A, Proenca-Modena JL, Carvalho RF, Mori MA, Martins-de-Souza D, Nakaya HI, Farias AS, Moraes-Vieira PM. Elevated Glucose Levels Favor SARS-CoV-2 Infection 693 694 and Monocyte Response through a HIF-1alpha/Glycolysis-Dependent Axis. Cell Metab 2020; 32: 437-446 e435. 695

28. Laviada-Molina HA, Leal-Berumen I, Rodriguez-Ayala E, Bastarrachea RA. Working
 Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between

698	the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of
699	BCG Vaccine? Front Endocrinol (Lausanne) 2020; 11: 514.
700	29. Tang J, Chen L, Qin ZH, Sheng R. Structure, regulation, and biological functions of TIGAR
701	and its role in diseases. Acta Pharmacol Sin 2021; 42: 1547-1555.
702	30. Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, Cai Z,
703	Han F, Xu C, Jin G, Sun L, Pan BS, Lai SW, Hsu CC, Xu J, Chen ZZ, Li HY, Seth P,
704	Hu J, Zhang X, Li H, Lin HK. Lactate Is a Natural Suppressor of RLR Signaling by
705	Targeting MAVS. Cell 2019; 178: 176-189 e115.
706	31. Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L, Li Q, Liu M, Tong Y, Chen L, Ru D,
707	Zhang T, Zhou K, Zhang B, Xu P, Yang Z, Li W, Song Y, Xu J, Zhu T, Shan F, Yu W,
708	Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently
709	blocking COVID-19 progression. Signal Transduct Target Ther 2022; 7: 91.
710	32. Ahmad I, Edin A, Granvik C, Kumm Persson L, Tevell S, Mansson E, Magnuson A,
711	Marklund I, Persson IL, Kauppi A, Ahlm C, Forsell MNE, Sundh J, Lange A, Cajander
712	S, Normark J. High prevalence of persistent symptoms and reduced health-related
713	quality of life 6 months after COVID-19. Front Public Health 2023; 11: 1104267.
714	33. Roffman CE, Buchanan J, Allison GT. Charlson Comorbidities Index. J Physiother 2016;
715	62: 171.
716	34. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
717	capture (REDCap)a metadata-driven methodology and workflow process for
718	providing translational research informatics support. J Biomed Inform 2009; 42: 377-
719	381.
720	35. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua
721	G, Delacqua F, Kirby J, Duda SN, Consortium RE. The REDCap consortium: Building
722	an international community of software platform partners. J Biomed Inform 2019; 95:
723	103208.
724	36. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
725	assigning sequence reads to genomic features. <i>Bioinformatics</i> 2014; 30: 923-930.
726	37. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
727	RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.

728


#### 729 **FIGURES**



730

## 731 Figure 1. Light sheet fluorescent microscopy (LSFM) of biopsies from deceased COVID-

19 patients displays a reduced alveolar surface. A) Schematic overview of LFSM procedure 732 with tissue biopsies from healthy donors (n=4), deceased COVID-19 patients (n=3) and 733 734 recovered COVID-19 patient (n=1). B-D) Maximum intensity projections of one representative biopsy from each patient group. Scale bar in D is 500 µm. E-G) LSFM sections and 735 magnifications showing the alveolar structure in each patient group. Scale bar in G is 500 µm 736 and scalebar in G' is 100 µm. H) Size distribution of alveolar diameter measured in LSFM 737 sections, ten random diameter measurements in five different z planes from each patient. I-K) 738 Iso-surfaced empty space in the lung biopsies as a proxy for alveolar volume. Scalebar in K is 739 400 µm and scalebar in K<sup>-</sup> is 100 µm. L) Quantification of the surface volume surrounding the 740 empty space as a proxy for alveolar surface volume. Statistical significance was calculated by 741 unpaired t-test (\*\*\*p < 0.001). 742



743

744 Figure 2. Lung necropsies and lung aspirates from severe COVID-19 patients show large amounts of hyaluronan (HA) and a high degree of HA fragmentation. A) Schematic 745 overview of collection of patient samples for HA analysis. B) Lung biopsies from the upper and 746

lower left lobe of five deceased COVID-19 patients were stained for HA. Scale bar is 1000 µm. 747 748 C) Collagen and HA staining in lung biopsies from healthy lung tissue (scale bar is 200 µm) and from a deceased COVID-19 patient (scale bar is 100 µm). The COVID-19 lung biopsy 749 750 shows areas with no alveoli structures. D) HA was isolated from the lung biopsies in B (n=5) and a size distribution analysis was performed with gas-phase electrophoretic mobility 751 molecular analysis (GEMMA). Shown is an average of all five patients. High molecular weight 752 753 HA with a known molecular size of 30 kDa was included as control. HA was also isolated and subjected to size analysis by GEMMA from E) nasopharyngeal aspirate and F) endotracheal 754 aspirate collected from three severe COVID-19 patients and displayed individually for each 755 756 patient.








Figure 3. High concentrations of hyaluronan (HA) in plasma are associated with COVID-758 759 **19 severity and long-term lung impairment.** A) HA concentrations in plasma from patients with severe and mild COVID-19 compared to controls (Ctrl). Samples were taken during the 760 acute phase (0-4 weeks from disease onset) and again during the convalescent phase of the 761 disease ( $\geq$ 12 weeks). HA concentrations were determined by ELISA. B-C) HA concentrations 762 in plasma during the acute phase grouped based on severity and B) sex or C) age. Each dot 763 represents one patient, and the line represents the median. Severity was based on WHO Clinical 764

Progression Scale (WHO-CPS) with patients requiring high-flow nasal oxygen treatment and/or 765 766 admission to the intensive care unit during the acute phase of illness classified as "severe", corresponding to WHO-CPS 6-9, and all other patients as "mild", WHO-CPS 1-5. Statistical 767 significance was calculated by Mann-Whitney U-test (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001). D-768 E) The percentage of predicted values of diffusion capacity (DL<sub>CO</sub>) related to HA 769 concentrations in plasma in D) the acute phase or E) the convalescent phase divided by sex and 770 771 disease severity. F-G) The percentage of predicted values of DL<sub>CO</sub> related to HA concentrations in plasma in D) the acute phase or E) the convalescent phase divided by age and disease 772 773 severity.





#### 775 Figure 4. Inflammatory response and effect of corticosteroid treatment in a SARS-CoV-2


776 infected 3D-lung model. A) Schematic overview of the primary 3D-lung model that was infected with SARS-CoV-2 in the presence or absence of corticosteroids to investigate the 777 778 effect on inflammation and hyaluronan metabolism. B) The lung cultures based on differentiated primary human bronchial epithelial cells at an air-liquid interface were pretreated 779 with/without betamethasone (Beta) in the basal media for 20 h prior to infection with SARS-780 781 CoV-2 (multiplicity of infection=0.5). The accumulated viral release from the apical side of the cultures was quantified by qPCR at indicated timepoints. C-D) Volcano plot showing 782 differentially expressed genes between C) infected vs uninfected (mock) lung cultures and D) 783 784 infected lung cultures with betamethasone vs without betamethasone treatment. The statistical *p*-value  $(-\log_{10})$  is plotted against the fold change in gene expression  $(\log_2)$ . Dotted lines 785 highlight the significance cut off corresponding to a fold change of 1.3 and p-value=0.05. E) 786 787 Heatmap displaying the mean expression  $(\log_2)$  of the overlapping genes in uninfected, infected and infected + betamethasone-treated lung cultures. F) Cytokine levels in basolateral samples 788 789 from HBEC ALI-cultures collected at 96 h post infection analyzed by Proximity Extension Assay (Olink). The gene expression levels of HA synthases G) HAS1, H) HAS2 and I) HAS3 790 along with the hyaluronidases J) HYAL1 and K) HYAL2 were determined by qPCR 120 h post 791 792 SARS-CoV-2 infection of lung cultures from two different donors (D1 and D2). L) HA concentrations were determined by ELISA in apical secretions from lung cultures 120 h post 793 infection. Mean values and SEM are shown, statistical significance was calculated by unpaired 794 t-test (\*p < 0.05, \*\*p < 0.01\*\*\*p < 0.001). 795

796

797

798

799



#### Figure 5. The effect of SARS-CoV-2 and betamethasone on cellular pathways regulating 801 802 IFN-I responses and hyaluronan (HA) production in a human in vitro 3D-lung model. Schematic presentation of a cell infected with SARS-CoV-2 with or without betamethasone 803 804 treatment and affected cellular pathways regulating A) the IFN-I response and B) HA production. The left side of the gene shows the effect on gene expression upon SARS-CoV-2 805 infection, and the right side shows effect of betamethasone treatment in infected lung cultures. 806 807 Blue color corresponds to an increase in gene expression and yellow indicates a decrease in gene expression. Viral genes are represented by dotted lines. 808

## 809 TABLES

# 810 Table 1. Demography and characteristics of COVID-19 patients.

Detient characteristics	G (NL 27)		n value
Patient characteristics	Severe (N=37)	Mild (N=66)	p-value
Demography A no N/ and	500(460640)	545(422(15))	0.594
Age, Years	58.0 (46.0-64.0)	54.5 (43.3-61.5)	0.584 0.112
Sex, Female N (%) BMI	11 (29.7)	31 (47.0) 26.3 (24.0-28.9)	0.112 <0.001
Obesity N (%)	30.5 (27.6-33.3) 20 (54.1)	20.3 (24.0-28.9) 15 (22.7)	<0.001 0.002
Comorbidities	20 (34.1)	13 (22.7)	0.002
Diabetes N (%)	4 (10.8)	5 (7.6)	0.719
Hypertension N (%)	12 (32.4)	17 (25.8)	0.719
Cardiovascular disease <sup><math>a</math></sup> N (%)	4 (10.8)	11 (16.7)	0.564
Chronic pulmonary disorder <sup>b</sup> N (%)	4 (10.8) 8 (21.6)	11 (16.7)	0.504
Autoimmune disease N (%)	2 (5.4)	5 (7.6)	1.000
Charlson comorbidity index	0 (0-1.0)	0 (0-0.8)	0.584
Smoking <sup>c</sup>	0 (0 1.0)	0 (0 0.0)	0.384
Smoker N (%)	1 (2.8)	1 (1.7)	0.207
Ex-smoker N (%)	13 (36.1)	14 (23.7)	
Laboratory findings	× /		
C-reactive protein, max $(mg/L)^d$	166 (84.5-278)	12 (3.1-76.0)	<0.001
Hemoglobin, min $g/L^e$	126 (105-133)	134 (121-144)	0.004
White bloodcell count, max (10e9/L) <sup>e</sup>	11.9 (8.9-16.1)	6.9 (5.4-8.0)	<0.001
Neutrophil count, max (10e9/L <sup>e</sup>	9.3 (6.0-12.3)	4.15 (2.9-5.1)	<0.001
Lymphocyte count, max (10e9/L) <sup>e</sup>	2.3 (1.7-2.3)	2.05 (1.7-2.4)	0.061
Platelet count, min (10e9/L) <sup>f</sup>	193 (167-233)	187 (134-232)	0.251
<i>P-Creatinine, max</i> $(\mu mol/L)^e$	79 (68.0-98.0)	77.5 (70.3-90.0)	0.975
Interleukin-6 max (ng/L) <sup>g</sup>	141 (27.3-353)	22 (14.3-35.8)	0.002
Treatment and respiratory support			
Corticosteroid treatment N (%)	32 (86.5)	4 (6.1)	<0.001
Remdesivir treatment N (%)	15 (40.5)	3 (4.5)	<0.001
Invasive mechanical ventilation N (%)	8 (21.6)	0 (0)	<0.001

811 Descriptive data of the patient cohort. All values presented as median and interquartile range if


not otherwise stated.

B13 Differences between groups analyzed by Mann-Whitney U-test (continuous variables) and
B14 Fisher's exact test (dichotomous variables), except when otherwise stated. No correction for

815 multiple testing was performed.


- <sup>a</sup>Including: Heart failure, ischemic heart disease, peripheral arterial insufficiency, deep venous
- 817 thrombosis, and pulmonary embolism.
- <sup>b</sup>Including: Asthma and chronic obstructive pulmonary disease.
- 819  $^{c}N=95$ , analysed by Chi<sup>2</sup> test,  $^{d}N=91$ ,  $^{e}N=93$ ,  $^{f}N=92$ ,  $^{g}N=66$
- 820

# 821 SUPPLEMENTARY INFORMATION



822

Supplementary figure 1. Light sheet fluorescent microscopy of biopsies from deceased
COVID-19 patients and healthy donors. Maximum intensity projections of three healthy
donors and two COVID-19 necropsies, scale bar is 500 µm.



Supplementary figure 2. Neutrophil infiltration of COVID-19 lung necropsy. Confocal 827 images on paraffin sections from healthy and COVID-19 lung biopsies stained with Dapi (blue) 828

and neutrophil elastase (green). Representative pictures from imaged biopsies, scalebar is 100 829

830 μm.

#### 831 Supplementary Table 1.

		DL <sub>co</sub> %pred	833
Variables	N (%)	β-coefficent (95% CI)	р
HA acute phase (log 2)		-5.62	0.042
		(-11.01 to -0.22)	
Sex			
Male	41 (58.6)	ref	
Female	29 (41.4)	3.74	0.448
		(-6.06 to 13.53)	
Chronic lung disease	14 (20)	-3.58	0.582
		(-16.54 to 9.37)	
Cardiovascular disease	10 (14.3)	-8.89	0.236
		(-23.74 to 5.97)	
Hypertension	19 (27.1)	-10.45	0.090
		(-22.58 to 1.68)	
Diabetes	4 (5.7)	4.69	0.647
		(-15.72 to 25.11)	
Smoker or previous smoker	20 (28.6)	-1.74	0.741
		(12.24 to 8.75)	
Obesity	23 (32.9)	1.27	0.810
		(-9.27 to 11.81)	
Severity of COVID-19			
Mild disease	42 (60)	ref	
Severe disease	28 (40)	-8.0	0.179
		(-19.77 to 3.76)	
Age groups (years)			
20-59	12 (17.1)	ref	
60-89	31 (44.3)	-0.08	0.988
		(-11.46 to 11.30)	

= 0.238, p < 0.003. Significance set at p < 0.05.

#### 851 Supplementary Table 2.

		DL <sub>co</sub> %pred	
Variables	N (%)	β-coefficent (95% CI)	р
HA convalescent phase (log 2)		-9.51	0.033
		(-18.21 to -0.82)	
Sex			
Male	41 (58.6)	ref	
Female	29 (41.4)	4.62	0.36
		(-5.45 to 14.68)	
Chronic lung disease	14 (20)	0.68	0.929
		(-14.63 to 15.99)	
Cardiovascular disease	10 (14.3)	-17.64	0.03
		(-33.48 to -1.80)	
Hypertension	19 (27.1)	-10.03	0.123
		(-22.88 to 2.83)	
Diabetes	4 (5.7)	-2.22	0.866
		(-28.57 to 24.13)	
Smoker or previous smoker	20 (28.6)	4.40	0.406
		(-6.15 to 14.96)	
Obesity	23 (32.9)	3.53	0.539
		(-7.95 to 15.01)	
Severity of COVID-19			
Mild disease	42 (60)	ref	
Severe disease	28 (40)	-13.99	0.014
		(-25.05 to -2.93)	
Age groups (years)			
20-59	12 (17.1)	ref	
60-89	31 (44.3)	4.14	0.48′
		(-7.58 to 15.87)	

852